CXCL8 and respiratory failure: The persistence of inflammation after the onset of pediatric acute respiratory failure in general, and in PARDS specifically, offers a unique opportunity to determine whether measuring plasma IL-8 over time can be used as an indicator of therapeutic effectiveness and/or disease progression.